Kalium phosphoricum comp. in patients with neurasthenia: a randomized, double-blind, placebo-controlled clinical trial
CONCLUSIONS: Trial treatment was well tolerated with only few and minor AEs reported, confirming the markedly good safety of KPC. A significant improvement of neurasthenia was seen for the total study population at the end of the treatment period. Superiority of KPC vs. placebo could not be demonstrated with the pre-specified analysis in regards to a sum score of 12 typical symptoms, perceived stress or general health status. However, the explorative post-hoc analysis revealed that KPC is superior to placebo in the characteristic symptoms irritability and nervousness. KPC could therefore be a beneficial treatment option for symptomatic relief of neurasthenia.PMID:38099469 | DOI:10.1080/03007995.2023.2291169
Source: Current Medical Research and Opinion - Category: Research Authors: Juliane Hellhammer Luitgard Spitznagel-Schminke Rebecca Hufnagel Source Type: research
More News: Brain | Clinical Trials | Germany Health | Neurology | Psychiatry | Research | Students | Study | Universities & Medical Training | Women